Project profile — Advance Market Commitment for Pneumococcal Vaccines (II)

Download project profile:



Advance Market Commitment for Pneumococcal Vaccines (II) - Overview
Advance Market Commitments (XM-DAC-44006)
2010-04-13 - 2020-12-31
Country / region • Africa, regional (25.00%)
• America, regional (25.00%)
• Asia, regional (25.00%)
• Europe, regional (25.00%)
Sector • Basic Health
Infectious disease control (12250) (100.00%)
Policy marker • Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)
Description and results


The Advance Market Commitment (AMC) is a financial commitment by multiple donors to help pay for the future purchase of a vaccine for pneumococcal disease, a leading cause of child deaths from pneumonia and meningitis in developing countries. Pneumococcal disease is responsible for more than 1.7 million deaths per year. Of these deaths, almost 90% occur in developing countries, and half occur among children under age five. The AMC is an innovative way to protect the lives of the world’s poorest children by making vaccines available in developing countries more quickly. It is based on the concept of putting money aside to guarantee the purchase of vaccines once they are developed as long as they meet criteria specifically set out for the developing world. It aims to stimulate vaccine makers to accelerate the production of vaccines for developing countries and sell them at prices that poor countries can afford. The AMC is expected to save an estimated 7 million lives by 2030. The total donor commitment to the AMC is US$1.5 billion. These funds allow for the implementation of the AMC concept by the World Bank and the GAVI Alliance. Canada's total commitment to the AMC is US$200 million, of which C$115 million have been disbursed. This project represents the balance of Canada's contribution, which is disbursed based on country demand for pneumococcal vaccines.

Results achieved

Results achieved by GAVI’s Advance Market Commitment through the support of Canada and other international donors during the period of 2010 to 2012 include: a total of 101 million doses produced and delivered, culminating in an estimated number of over 10 million children in 24 countries immunized against today’s main cause of pneumonia.



Original budget $0
Planned Disbursement $0
Country Percentages by Sector
Related information

Related information

Advance Market Commitment for Pneumococcal Vaccines (II) - Related information
Related activities
Advance Market Commitment for Pneumococcal Vaccines (I)
Related links
Global Affairs Canada
MFM Global Issues & Dev.Branch
Aid grant excluding debt reorganisation
Core contributions to multilateral institutions

The coloured circles represent the number of markers in proximity. Simply click on the circle to zoom in for more information on projects.

2 to 9 markers 10 to 99 markers 100 to 999 markers 1,000 to 9,999 markers

Note: The Project Browser provides access to project data published by Global Affairs Canada in accordance with the International Aid Transparency Initiative (IATI) standard. This is not meant for official reporting, but to provide information on past and current international projects.

Date modified: